Satellos Bioscience Inc.

OTCPK:MSCL.F Stock Report

Market Cap: US$69.5m

Satellos Bioscience Future Growth

Future criteria checks 0/6

Satellos Bioscience's earnings are forecast to decline at 17.1% per annum. EPS is expected to decline by 0.1% per annum.

Key information

-17.1%

Earnings growth rate

-0.1%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated23 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:MSCL.F - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-31N/A-272
12/31/2025N/A-26N/A-222
12/31/2024N/A-25N/A-222
6/30/2024N/A-23-22-22N/A
3/31/2024N/A-21-20-20N/A
12/31/2023N/A-16-15-15N/A
9/30/2023N/A-14-10-10N/A
6/30/2023N/A-13-8-8N/A
3/31/2023N/A-11-5-5N/A
12/31/2022N/A-11-6-6N/A
9/30/2022N/A-9-6-6N/A
6/30/2022N/A-18-7-7N/A
3/31/2022N/A-17-7-7N/A
12/31/2021N/A-16-5-5N/A
9/30/2021N/A-13-5-5N/A
6/30/20210-2-2-2N/A
3/31/2021N/A-2-1-1N/A
12/31/2020N/A-2-2-2N/A
12/31/20190-2-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MSCL.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MSCL.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MSCL.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MSCL.F's revenue is forecast to grow faster than the US market.

High Growth Revenue: MSCL.F is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MSCL.F's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y